Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (129)	11/8/1998 1:02:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1386

Ariella Your web research is great ahead of Globes globes.co.il

To: Ariella who wrote (129)	11/9/1998 2:31:00 AM
From: Tony van Werkhooven	Read Replies (1) \| Respond to of 1386

Ariella- Is BOL responsible for all product costs (i.e ingredients, packaging, marketing etc)? Hence, essentially all payments for BOL can fall to the bottom line or available to meet development costs on new products in the pipeline. With respect to 3rd quarter sales- do you or anyone have a sense of the impact of physician samples might have in deferring the writing of Rx. I presume that with the product introductions by BOL physicians have been amply supplied with samples. To the extent samples are available, a physician can provide these to his/her patient instead of an Rx. Any comments would be appreciated. Do we have any idea of the volume of samples distributed? Am I off on an irrelevant tangent? Thanks Tony